Back to results
US 2022/0281835 A1Published application
Phenol derivatives for use as antimicrobial, antibacterial, bactericide
AssigneeSpecial Product's Line S.P.A.
InventorsSabrina DALLAVALLE, Claudio PISANO, Massimiliano FLORIO, Claudio CAMPONESCHI
Life of this patent
Estimating the term…
Abstract
Phenol derivatives of general formula (I) and (II), wherein meanings of the substituents are indicated in the description, their pharmaceutically acceptable salts, together with the processes for their preparation, their use as antimicrobial, antibacterial, bactericide agents and the corresponding pharmaceutical compositions are disclosed.
Claims20
1:
- A compound having a structure as set forth in formula (II)
- wherein B is C3-C12 cycloalkyl, or phenyl, or a C3-C13 heterocycle containing S, N, O
- R1 is H, C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl linear or branched C3-C12 cycloalkyl optionally substituted with C1-C4 alkyl or OH, C1-C3 arylalkyl, phenyl, optionally substituted with C1-C4 alkyl, C1-C4 alkenyl, C1-C4 alkynyl linear or branched, heterocycle containing at least one heteroatom selected from the group consisting of:
- N, O, S, optionally substituted with OH, NH2,
- R2 is C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl linear or branched, (CH2)n-R7, (CH2)nO(CH2)mO—(CH2)p-R8, (CH2O)nCH3, CO—R8, (CH2)n-R10, D-mannosyl, glucuronate, (SO2)OH,
- R7 is OH, COOH, CONHO—R8, (CH2)nO(CH2)mO—R8, CN, NH2,
- R8 is H, C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl linear or branched,
- R10 is NH2, N-containing heterocycle, amidine, guanidine,
- R3 is H, OH, CHO, or
- R2 and R3 are linked to form a cycle comprising at least one atom of O and/or N,
- R4 is H,
- R5 is H, OH, C1-C5 alkyl, C1-C5 alkenyl, C1-C5 alkynyl linear or branched, (CH2)—R11, CHO, CH═NOH, CH═NO—R14, CH═NO—(CH2)n-COOH, CH═NO—(CH2)n-NH2, (CH2nNHCO—R14, (CH2)nNHCO-Aryl, (CH2)—R15,
- R11 is OH, NH2, N—R12R13,
- R12 and R13, the same or different are, H, C1-C5 alkyl, C1-C5 alkenyl, C1-C5 alkynyl linear or branched, C(═NH)NH2,
- R15 is a heterocycle containing N, O, S,
- R6 is C≡CCOOH, C≡CCH2OH, C≡C—CH═NOH, C≡C—C(R17)2OH, C≡CCOO—R14, C≡CCONH2, C≡C(CH3)2OH, C≡CONH—R14, C≡CCONHOH, C≡C-tetrazolyl C≡CCOO glycosyl,
- R14 is C2-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl linear or branched, C3-C12 cycloakyl, aryl, C1-C3 arylalkyl,
- R17 is C2-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl linear or branched,
- n is an integer from 1 to 15,
- m is an integer from 1 to 15,
- p is an integer from 1 to 15,
- with the proviso that when R6 is C≡COOH or C≡CCOOCH3 and R1 is H or adamantly and R2 is H or CH3, R3 and R5 are not both H,
- or a pharmaceutically acceptable salt thereof.
20 more elements
2:
- A compound having a structure as set forth in formula (II)
- wherein
- B is C3-C12 cycloakyl, or phenyl, or a C3-C13 heterocycle containing S, N, O,
- R1 is H, C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl linear or branched, C3-C12 cycloalkyl optionally substituted with C1-C4 alkyl or OH, C1-C3 arylalkyl, phenyl, optionally substituted with C1-C4 alkyl, linear or branched, heterocycle containing at least one heteroatom selected from the group consisting of:
- N, O, S, optionally substituted with OH, NH2,
- R2 is H, C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl linear or branched, (CH2)n—R7, (CH2)nO(CH2)mO—(CH2)p—R8, (CH2O)nCH3, CO—R8, (CH2)n—R10, D-mannosyl, glucuronate, (SO2)OH,
- R7 is OH, COOH, CONHO—R8, (CH2)nO(CH2)mO—R8, CN, NH2,
- R8 is H, C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl linear or branched,
- R10 is NH2, N-containing heterocycle, amidine, guanidine,
- R3 is H, OH, CHO, or
- R2 and R3 are linked to form a cycle comprising at least one atom of O, and/or N,
- R4 is H,
- R5 is H, OH, C1-C5 alkyl, C1-C5 alkenyl, C1-C5 alkynyl linear or branched, (CH2)—R11, CHO, CH═NOH, CH═NO—R14, CH═NO—(CH2)n—COOH, CH═NO—(CH2)n—NH2, (CH2)nNHCO—R14, (CH2)nNHCO-Aryl, (CH2)—R15
- R11 is OH, NH2, N—R12R13,
- R12 and R13, the same or different are, H, C1-C5 alkyl, C1-C5 alkenyl, C1-C5 alkynyl linear or branched, C(═NH)NH2,
- R14 is H, C1-C5 alkyl, C1-C5 alkenyl, C1-C5 alkynyl linear or branched, C3-C12 cycloakyl, aryl, C1-C3 arylalkyl,
- Optionally R4 and R5 can be joined together to form CH═CH or CO or O or S or SO or SO2
- R6 is CX═CYCOOH, CX═CYCN, CX═CYCH═NOH, CX═CYCOO—R14, CX═CYCONH2, CX═CY—CONH—R14, CX═CYCONHOH, CX═CY tetrazolyl, CX═CYCH2OH, CX═CY—P(═O)(O—R14)2, CX═CYCOO glycosyl,
- X is H, C2-C4 alkyl linear or branched, halogen, CN,
- Y is H, C2-C4 alkyl linear or branched, halogen, CN,
- n is an integer from 1 to 15,
- m is an integer from 1 to 15,
- p is an integer from 1 to 15,
- with the proviso that when R1 is adamantyl and R5 is hydrogen, R6 is not CX═CY—COOH or CX═CY—COOCH3 or CX═CY—COOCH2CH3,
- or a pharmaceutically acceptable salt thereof.
22 more elements
3:
- A compound having a structure as set forth in formula (II)
- wherein
- B is C3-C12 cycloakyl, or phenyl, or a C3-C13 heterocycle containing S, N, O,
- R1 is H, C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl linear or branched, C3-C12 cycloalkyl optionally substituted with C1-C4 alkyl or OH, C1-C3 arylalkyl, phenyl, optionally substituted with C1-C4 alkyl, linear or branched, heterocycle containing at least one heteroatom selected from the group consisting of:
- N, O, S, optionally substituted with OH, NH2,
- R2 is H, C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl linear or branched, (CH2)n—R7, (CH2)nO(CH2)mO—(CH2)p-R8, (CH2O)n CH3, CO—R8, (CH2)n—R10, D-mannosyl, glucuronate, (SO2)OH,
- R7 is OH, COOH, CONHO—R8, (CH2)nO(CH2)mO—R8, CN, NH2,
- R8 is H, C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl linear or branched,
- R10 is NH2, N-containing heterocycle, amidine, guanidine,
- R3 is H, OH, CHO, or
- R2 and R3 are linked to form a cycle comprising at least one atom of O and/or N,
- R4 is H,
- R5 is CH═NO—R14, CH═NO—(CH2)n—NH2, (CH2)nNHCO—R14,
- R14 is H, C1-C5 alkyl, C1-C5 alkenyl, C1-C5 alkynyl linear or branched, C3-C12 cycloakyl, aryl, C1-C3 arylalkyl, (CH2)n-COOH,
- R4 and R5 can be joined together to form CH═CH or CO or O or S or SO or SO2,
- R6 is ═CHCOOH, (CH2)nCH═NOH, ═CHCOOR16, CX═CYCOOH, CX═CYCN, CX═CYCOO—R16, CX═CY-tetrazolyl, CX═CYCONH2, CX═CY—CONH—R16, CX═CYCONH-aryl, CX═CYCONHOH, CX═CYCH2OH, C≡CCOOH, C≡CCH2OH, C≡CCOO—R16, C≡CCONH2, C≡CONH—R16, C≡CCONH-aryl, C≡CCONHOH, CX═CYCOO glycosyl, C≡CCOO glycosyl,
- R16 is H, C2-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl linear or branched, C3-C12 cycloakyl, aryl, C1-C3 arylalkyl, (CH2)n-COOH,
- X and Y, the same or different, are H, C2-C4 alkyl linear or branched, halogen, CN,
- n is an integer from 1 to 8,
- with the proviso that when R14 is H, CH3, tert-butyl or (CH2)COOH, R6 is not CH═CH—COOH,
- or a pharmaceutically acceptable salt thereof.
18 more elements
4:
- A compound as set forth in claim 1, formulated as a medicament.
5:
- A compound as set forth in claim 1, formulated as antimicrobial and/or antibacterial and/or bactericide.
6:
- A compound having a structure as set forth in formula (I):
- wherein
- A is absent or is CW═CZ
- B is C3-C12 cycloakyl, or phenyl, or a C3-C13 heterocycle containing S, N, O,
- R1 is H, C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl linear or branched, C3-C12 cycloalkyl optionally substituted with C1-C4 alkyl or OH, C1-C3 arylalkyl, phenyl, optionally substituted with C1-C4 alkyl linear or branched, or with a C3-C13 heterocycle containing at least one heteroatom selected from the group consisting of:
- N, O, S or C3-C13 optionally substituted with OH, NH2,
- R2 is H, C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl linear or branched, (CH2)n—R7, (CH2)nO(CH2)mO—(CH2)p-R8, (CH2O)n CH3, CO—R8, CO—R9, (CH2)n—R10, monosaccharide residue, glycosyl, glucuronate, (SO2)OH,
- R7 is OH, COOH, CONHO—R8, (CH2)nO(CH2)mO—R8, CN, NH2,
- R8 is H, C1-C18 alkyl, C1-C18 alkenyl, C1-C18 alkynyl linear or branched optionally substituted with NH2, cycloalkyl optionally substituted with NH2,
- R9 is aryl, C1-C5 alkyl-aryl,
- R10 is an heterocycle containing at least one N, amidine, guanidine
- R3 is H, OH or (CH2)nNH2, (CH2)nOH, CHO, NHCO—R18, NHCONH—R18, or
- R2 and R3 are linked to form a cycle comprising at least one atom of O and/or N,
- R4 is H,
- R5 is H, CH3, OH, C1-C5 alkyl, C1-C5 alkenyl, C1-C5 alkynyl linear or branched, (CH2)n—R11, CHO, CH═NOH, CH═NO—R14, CH═NO—(CH2)n—COOH, CH═NO—(CH2)n—NH2, CH═NO(CH2)n—OH, (CH2)nNHCO—R14, (CH2)—R15, CH═NO—R14, CH2OH, COCH3, COOH, (CH2)nNH—R17, (CH2)nN(R17)2,
- R11 is OH, NH2, N—R12R13,
- R12 and R13, the same or different are, H, C1-C5 alkyl, C1-C5 alkenyl, C1-C5 alkynyl linear or branched, C(═NH)NH2
- R15 is an heterocycle containing N, O, S,
- R6 is CH2OH, CHO, CH═NOH, COOH, CONHOH, (CH2)nCOOH, (CH2)nCONHOH, (CH2)nNHOH, (CH2)nCH═NOH, CX═CY—CHO═CHCOOH, ═CHCOOR14, CX═CYCOOH, CX═CYCN, CX═CY-tetrazolyl, CX═CYCOO—R14, CX═CYCONH2, CX═CY—CONH—R14, CX═CYCONHOH, CX═CYCH2OH, CX═CY—P(═O)(O—R14)2, C≡CCOOH C≡C-tetrazolyl, C≡CCH2OH, C≡CC(alkyl)2OH, C≡CCOO—R14, C≡CCONH2, C≡CONH—R14, C≡CCONH-aryl, C≡CCONHOH, COO-glycosyl, CX═CYCOO-glycosyl, C≡CCOO-glycosyl,
- X and Y, the same or different, are H, C2-C4 alkyl linear or branched, halogen, CN, or
- X and Y together form an C3-C6 cycloalkyl or a C3-C6 heterocycle containing N, O, S,
- R14 is C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl linear or branched, C3-C12 cycloakyl, aryl, C1-C3 arylalkyl, C(═NH)NH2,
- R17 is C2-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl linear or branched,
- R18 is C2-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl linear or branched, aryl,
- W and Z, the same or different, are H, C2-C4 alkyl linear or branched, halogen, CN,
- n is an integer from 1 to 15,
- m is an integer from 1 to 15,
- p is an integer from 1 to 15,
- with the proviso that when A is CW═CZ R2 is hydrogen and R1 and R5 are not hydrogen,
- optionally when A is CW═CZ and B is phenyl, A can form a heterocyclic ring containing O, N, S with the phenyl ring,
- optionally when A is absent R4 and R5 can be joined together to form CH═CH, CO, O, S, SO, SO2,
- or a pharmaceutically acceptable salt thereof, for use as antimicrobial and/or antibacterial and/or bactericide.
29 more elements
7:
- A pharmaceutical composition comprising:
- (a) at least one compound of claim 1 as an active ingredient;
- and (b) a pharmaceutically acceptable adjuvant, a vehicle or an excipient.
8:
- A method for treating a microbial infection comprising administering to an individual in need thereof a compound as set forth in claim 1.
9:
- A method for treating a microbial infection comprising administering to an individual in need thereof a compound as set forth in claim 2.
10:
- A method for treating a microbial infection comprising administering to an individual in need thereof a compound as set forth in claim 3.
11:
- A method for treating a microbial infection comprising administering to an individual in need thereof a compound as set forth in claim 6.
12:
- The method of claim 8, wherein the microbial infection is a bacterial, viral, fungal, protozoal or parasite infection.
13:
- The method of claim 12, wherein the bacterial infection is a gram-positive or a gram-negative bacterial infection.
14:
- The method of claim 13, wherein the gram-positive or a gram-negative bacterial infection is an infection caused by a:
- Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, or Streptococcus thermophilus.
15:
- The method of claim 9, wherein the microbial infection is a bacterial, viral, fungal, protozoal or parasite infection.
16:
- The method of claim 15, wherein the bacterial infection is a gram-positive or a gram-negative bacterial infection.
17:
- The method of claim 16, wherein the gram-positive or a gram-negative bacterial infection is an infection caused by a:
- Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, or Streptococcus thermophilus.
18:
- The method of claim 10, wherein the microbial infection is a bacterial, viral, fungal, protozoal or parasite infection.
19:
- The method of claim 18, wherein the bacterial infection is a gram-positive or a gram-negative bacterial infection.
20:
- The method of claim 19, wherein the gram-positive or a gram-negative bacterial infection is an infection caused by a:
- Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, or Streptococcus thermophilus.